Biotech news
Americas
Delhi High Court has granted an interim injunction against Zydus Lifesciences over the company’s proposed nivolumab product | BMS’s Indian patent covering the monoclonal antibody expires in May 2026. 21 July 2025
Americas
This LSPN session features experts from EIP, The Broad Institute of MIT and Harvard, Pfizer, and an independent specialist discussing the protection of life science innovations involving big data, AI, and machine learning. 21 July 2025
Americas
Experts from Dechert, BlueRock Therapeutics, Merck, Seaport Therapeutics, and Ventus Therapeutics examine the impact of recent court rulings following Amgen v. Sanofi on broad genus claims within life sciences patents, as discussed at LSPN. 18 July 2025
Americas
LSPN experts from Goodwin Law, Invivyd, and New England Biolabs discuss the challenges of patent eligibility under 35 U.S.C. § 101 in life sciences innovation. The session explores strategies to address obstacles arising from recent court decisions and USPTO guidelines. 16 July 2025
Europe
After almost 30 years as head of IP at Bayer, Jörg Thomaier is to retire and is handing the baton to Dorian Immler. Speaking to Sarah Speight, the pair explain what makes a good IP strategy, why the UPC is largely “useless” without SPCs, and more. 15 July 2025
Africa
Africa’s agricultural future is imperative to life and prosperity in the region—and the Arusha Protocol gives breeders the protection they need, explains the African Regional Intellectual Property Organization. 15 July 2025
Biotech
LSPN brings together experts from Venable, Ipsen, Stoke Therapeutics, and Biogen to analyse best practices for IP transactions, from due diligence and valuation to structuring deals. 8 July 2025
Europe
Board of Appeal upholds opposition challenge over added subject-matter claims | Dispute concerned patent relating to T cell therapeutic manufacturing methods. 3 July 2025
Americas
Biocon failed to provide critical information about proposed denosumab product, Amgen claims | Company expects ‘sales erosion’ of Prolia and XGEVA in 2025 driven by biosimilar competition | Sandoz launched interchangeable versions of bone drugs last month following settlement in 2024. 2 July 2025
Americas
Judge says sale of genetic data is ‘scary proposition’ but that blanket ban could result in missed opportunities | Former CEO Anne Wojcicki will repurchase business that she co-founded and ran for years. 1 July 2025